Literature DB >> 25820099

Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.

James N Wilson1, Wenjun Liu, Adrienne S Brown, Ralf Landgraf.   

Abstract

We report the photophysical properties, binding-induced turn-on emission, and fluorescence imaging of the cellular uptake and distribution of lapatinib, an EGFR/ERBB inhibitor. Lapatinib, a type II, i.e. inactive state, inhibitor that targets the ATP binding pocket of the EGFR family of receptor tyrosine kinases. DFT calculations predict that the 6-furanylquinazoline core of lapatinib should exhibit an excited state with charge transfer character and an S0 to S1 transition energy of 3.4 eV. Absorption confirms an optical transition in the near UV to violet, while fluorescence spectroscopy shows that photoemission is highly sensitive to solvent polarity. The hydrophobicity of lapatinib leads to fluorescent aggregates in solution, however, binding to the lipid-carrier protein, BSA or to the kinase domain of ERBB2, produces spectroscopically distinct photoemission. Confocal fluorescence microscopy imaging of lapatinib uptake in ERBB2-overexpressing MCF7 and BT474 cells reveals pools of intracellular inhibitor with emission profiles consistent with aggregated lapatinib.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820099      PMCID: PMC4548262          DOI: 10.1039/c5ob00239g

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  24 in total

1.  Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate.

Authors:  Joel W Schwartz; Randy D Blakely; Louis J DeFelice
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

2.  Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.

Authors:  Wanping Xu; Xitong Yuan; Kristin Beebe; Zhexin Xiang; Len Neckers
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

3.  Synthesis and properties of size-expanded DNAs: toward designed, functional genetic systems.

Authors:  Andrew T Krueger; Haige Lu; Alex H F Lee; Eric T Kool
Journal:  Acc Chem Res       Date:  2007-02       Impact factor: 22.384

4.  Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.

Authors:  Perry S Brignola; Karen Lackey; Sue H Kadwell; Christine Hoffman; Earnest Horne; H Luke Carter; J Darren Stuart; Kevin Blackburn; Mary B Moyer; Krystal J Alligood; Wilson B Knight; Edgar R Wood
Journal:  J Biol Chem       Date:  2001-11-05       Impact factor: 5.157

Review 5.  The role of overexpressed HER2 in transformation.

Authors:  R M Neve; H A Lane; N E Hynes
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

Authors:  Rosana Sáez; Miguel A Molina; Elizabeth E Ramsey; Federico Rojo; Edward J Keenan; Joan Albanell; Ana Lluch; Javier García-Conde; José Baselga; Gail M Clinton
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

7.  NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

Authors:  Miguel A Molina; Rosana Sáez; Elizabeth E Ramsey; María-José Garcia-Barchino; Federico Rojo; Adam J Evans; Joan Albanell; Edward J Keenan; Ana Lluch; Javier García-Conde; José Baselga; Gail M Clinton
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

8.  Substrate binding stoichiometry and kinetics of the norepinephrine transporter.

Authors:  Joel W Schwartz; Gaia Novarino; David W Piston; Louis J DeFelice
Journal:  J Biol Chem       Date:  2005-03-09       Impact factor: 5.157

9.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

10.  ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.

Authors:  Heini Lassus; Arto Leminen; Aki Vayrynen; Guojun Cheng; Jan-Ake Gustafsson; Jorma Isola; Ralf Butzow
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

View more
  4 in total

1.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.

Authors:  Matthew J Hangauer; Vasanthi S Viswanathan; Matthew J Ryan; Dhruv Bole; John K Eaton; Alexandre Matov; Jacqueline Galeas; Harshil D Dhruv; Michael E Berens; Stuart L Schreiber; Frank McCormick; Michael T McManus
Journal:  Nature       Date:  2017-11-01       Impact factor: 49.962

Review 2.  Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.

Authors:  Maria Krchniakova; Jan Skoda; Jakub Neradil; Petr Chlapek; Renata Veselska
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 3.  Intrinsically Fluorescent Anti-Cancer Drugs.

Authors:  Md Lutful Kabir; Feng Wang; Andrew H A Clayton
Journal:  Biology (Basel)       Date:  2022-07-28

4.  Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations.

Authors:  Inmaculada Andreu; Emilio Lence; Concepción González-Bello; Cristobalina Mayorga; M Consuelo Cuquerella; Ignacio Vayá; Miguel A Miranda
Journal:  Front Pharmacol       Date:  2020-10-30       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.